Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.73 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.58 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.58 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.58 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.58 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.58 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702178 | 1.00 | RET (0.73) | RETRPS6KA3LRRK2PSEN1PSEN2 | |
| SCHEMBL10091765 | 0.87 | RET (0.56) | RETRPS6KA3LRRK2PSEN1PSEN2 | |
| SCHEMBL5369248 | 0.82 | RET (0.65) | RETRPS6KA3LRRK2PSEN1PSEN2 | |
| SCHEMBL10091750 | 0.81 | RPS6KA3 (0.59) | RETRPS6KA3LRRK2PSEN1PSEN2 | |
| SCHEMBL701928 | 0.81 | RPS6KA3 (0.59) | RETRPS6KA3LRRK2PSEN1PSEN2 | |
| SCHEMBL701927 | 0.81 | RPS6KA3 (0.59) | RETRPS6KA3LRRK2PSEN1PSEN2 | |
| SCHEMBL701968 | 0.81 | POLB (0.70) | RETRPS6KA3PTPN1 | |
| SCHEMBL6001779 | 0.81 | POLB (0.70) | RETRPS6KA3PTPN1 | |
| SCHEMBL701967 | 0.81 | POLB (0.70) | RETRPS6KA3PTPN1 | |
| SCHEMBL5357946 | 0.78 | RET (0.64) | RETRPS6KA3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307421-A1 | OXINDOLE COMPOUNDS | Cylene Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041635-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | RET 164/4885RPS6KA3 290/4885LRRK2 604/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | RET 164/4885RPS6KA3 290/4885LRRK2 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.